

# Samuel Charles Fehling, PhD

☎ ( ) - | 📍 Hoover, Alabama | 💻 career.nerdyspace.net | ✉ sfehling@nerdyspace.net

## Professional Profile

- Detail-oriented biomedical scientist with 10+ years' experience designing and executing preclinical studies for rare diseases and molecular diagnostics.
- Skilled in pharmacological evaluation, protocol development & cross-functional preclinical coordination.

## Education

**University of Alabama at Birmingham (UAB)**

📍 Birmingham, AL

***Doctor of Philosophy in Biomedical Sciences***

December 2019

**University of Wisconsin – Eau Claire (UWEC)**

📍 Eau Claire, WI

***Bachelor of Science in Biochemistry & Molecular Biology***

May 2014

## Work Experience

***Sr. Research Biologist at BioCryst Pharmaceuticals Inc.***

2022 – Present

- Designed, validated, and conducted *in vitro* and *in vivo* studies to characterize pharmacological properties and efficacy of small molecule drug candidates in preclinical models.
- Coordinated cross-functional collaboration and contributed to protocol development and project management to support advancement of investigational drugs.

***Research & Development Scientist at BioGX***

2020 – 2022

- Developed molecular diagnostic assays for custom order & FDA EUA-approved products.
- Skilled in various industry areas including R&D, Quality Control & training of personnel.
- Assisted in developing new product line, product platform conversions & a new PCR platform.
- Experienced in PCR platforms including BD MAX, QuantStudio, Bio-Rad CFX & ABI 7500.
- Improved upon current procedures & approaches to save development down-time & money spent.

***University of Alabama at Birmingham (UAB) Graduate Research Assistant***

2014 – 2019

- Developed & analyzed therapeutic drug combinations targeting liver cancer (cholangiocarcinoma).
- Established and characterized chemotherapeutic-resistant liver cancer models using innovative *in vitro* and *in vivo* techniques.
- Skilled in handling athymic nude and C57BL/6 mice, performing oral gavage, intraperitoneal injections, and managing patient-derived xenograft (PDX) models.

## Selected Publications

Aubrey L. Miller, **Samuel C. Fehling**, Rebecca B. Vance, Dongquan Chen, Eric Josh Brown, M Iqbal Hossain, Eric O. Heard, Shaida Andrabi, Hengbin Wang, Eddy S. Yang, Donald J. Buchsbaum, Robert CAM van Waardenburg, Susan L. Bellis, Karina J. Yoon (2024). *BET Inhibition Decreases HMGCs2 and Sensitizes Resistant Pancreatic Tumors to Gemcitabine*. Cancer Letters.

Aubrey L. Miller, Patrick L. Garcia, **Samuel C. Fehling**, Tracy L. Gamblin, Rebecca B. Vance, Leona N. Council, Dongquan Chen, Eddy S. Yang, Robert CAM van Waardenburg, Karina J. Yoon (2021). *The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer*. Cancers.

**Samuel C. Fehling**, Aubrey L. Miller, Patrick L. Garcia, Rebecca B. Vance, Karina J. Yoon (2019). *The Combination of BET and PARP Inhibitors is Synergistic in Models of Cholangiocarcinoma*. Cancer Letters.